Innovation

A New Generation of Potent Adjuvants

Schepens Eye Research Institute
posted on 03/04/2009

Adjuvants such as alum are used in vaccination to promote the immune response. The bacterial-based adjuvants augment antigen-presenting cell activity to enhance the immunogenicity of the vaccine, but such adjuvants cause severe inflammatory reactions. Specific neuropeptides found in the eye modulate innate and adaptive immunity and can be used to promote immunity associated with vaccination and to minimize the side-effects of immunization. The combination of a neuropeptide with an immunogen modifies the immune response to the immunogen according to the specific need: induction or suppression of vaccine induced inflammation or specific cellular immunity. The technology finds applications in vaccination, immunotherapy and in the development of treatments against autoimmune diseases.


Innovation Details
 

File Number: SERI-145 

Other Information:

Investigator(s)
Ph.D. Andrew Taylor

Contact
Mary Chatterton, Director of Corporate Alliances. mary.chatterton@schepens.harvard.edu.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at Schepens Eye Research Institute for more information.

Request more info via email request more info
People

No people are currently associated with this innovation.


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

13,206 members 17,551 innovations 176 organizations

Browse

Alfred R Berkeley, Chairman, Pipeline Financial Group, Inc., Former President and Vice Chairman, Nasdaq Stock Market, Inc.

"Our economy is inextricably intertwined with university innovations. Unfortunately, our country’s short-term outlook often interferes with the long-term possibilities of university research and collaborations with industry and entrepreneurs..."  read more...